TuHURA Biosciences, Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand how TuHURA Biosciences performed this year. My goal is to explain their financial filings in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

TuHURA is a biotech company in the research phase. They focus on "immuno-oncology," which means teaching your immune system to find and kill cancer. Because they are still testing their treatments, they do not generate revenue from product sales.

Their primary focus is overcoming the mechanisms cancer cells use to hide from the immune system. Their lead product, IFx-2.0, is a personalized vaccine designed to help the immune system identify "cold" tumors, effectively turning them into "hot" targets that the body can recognize and attack.

2. The Big Strategy: Mergers and New Tech

The merger with Kineta, Inc., which closed in late 2024, established TuHURA as a public company on the Nasdaq (ticker: THUB). This move combined two distinct research pipelines:

• IFx Technology: This uses a proprietary protein to make tumor cells appear as foreign invaders, triggering an immune response.
• VISTA & DOR Tech: Through the Kineta acquisition, the company added TBS-2025 to its pipeline. This drug is designed to block a protein that cancer uses to suppress the immune system. They are also developing targeted therapies intended to deliver medicine directly into the tumor site.

3. Financial Health: The "Burn"

The company is currently pre-revenue and has invested over $150 million in research and development to date. As of March 2026, they had approximately 63.6 million shares outstanding. To sustain operations, the company utilizes three primary funding strategies:

• Equity Financing: They issue new shares to raise capital for clinical trials. Investors should note that this process increases the total share count, which reduces the ownership percentage of existing shareholders.
• Debt and Private Capital: They utilize loans and private investment vehicles to bridge gaps in cash flow.
• Strategic Partnerships: The company is actively pursuing agreements with large pharmaceutical firms. These deals typically involve upfront payments, milestone-based funding for research goals, and future royalties on product sales.

4. What’s Next?

The company is operating on a specific clinical timeline. They plan to engage with the FDA in early 2026 to finalize the design for a Phase 2 trial of TBS-2025, with the goal of beginning patient testing by late 2026. Simultaneously, they are working to expedite the regulatory pathway for IFx-2.0, targeting a potential market entry between 2027 and 2028.

5. Risks: What to Consider

• Cash Runway: Current cash reserves are projected to last until mid-2026. Securing additional funding or a partnership is essential for the company to continue its operations beyond that point.
• Clinical Outcomes: As a biotech firm, the company’s value is tied to the success of its trials. If clinical data fails to demonstrate that their drugs are safe and effective, the company’s valuation could be negatively impacted.
• Share Dilution: Because the company does not yet have product revenue, it relies on issuing new shares to fund its research. This practice lowers the value of existing shares.
• Operational Integration: The success of the Kineta merger depends on the effective combination of research teams, data, and resources.

Investor Takeaway: TuHURA is a high-risk, high-reward opportunity typical of early-stage biotech. Your decision should weigh their promising, multi-faceted research pipeline against the reality that they are currently burning cash, have no product revenue, and will likely need to raise more money or secure a major partnership to reach their clinical goals.